Janney Capital


Nike Wows Investors With A Stellar Q1

Nike, Inc. (NYSE: NKE) is a Beaverton, Oregon based American multinational corporation that designs, develops, manufactures and sells athletic footwear, apparel, equipment and accessories …

Janney Capital Remains Neutral On PDL Biopharma Following The Resign Of Ernst & Young

In a research note released today, Janney Capital analyst Kimberly Lee maintained a Neutral rating on PDL Biopharma (PDLI) with a $7 fair value, following the reporting that the …

Janney Reiterates Buy On CTI BioPharma Following Collaboration Agreement With Servier

In a research note published today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Cell Therapeutics (NASDAQ:CTIC) with a $4 fair value, following collaboration agreement with …

Janney Capital Reiterates Buy On Agile Therapeutics Following Initiation Of Phase III Twirla Study

In a research note released today, Janney Capital analyst Kimberly Lee reiterated a Buy rating on Agile Therapeutics (NASDAQ:AGRX) with an $18 fair value …

Janney Reiterates Buy On NPS Pharmaceuticals As FDA Panel Backs Natpara Approval

In a report released today, Janney Capital analyst Kimberly Lee reiterated a Buy rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a $37 fair value, following last friday’s news …

Janney Capital Reiterates Buy On NPS Pharma Ahead Of FDA Meeting For Natpara

In a research note published yesterday, Janney Capital analyst Kimberly Lee reiterated a Buy rating on NPS Pharma (NASDAQ:NPSP) with a $37 fair …

Janney Capital Keeps Buy On Medivation Following Label Expansion On Xtandi

In a research report pubished yesterday, Janney Capital analyst Kimberly Lee maintained a Buy rating on Medivation (NASDAQ:MDVN) with a $110 fair value, …

We Remain Constructive On NPSP Shares Ahead Of The Upcoming FDA AdCom, Says Janney

In a research report released today, Janney Capital analyst Kimberly Lee reiterated a Buy rating on NPS Pharmaceuticals (NPSP) with a $37 fair value, ahead of the company’s upcoming …

Janney Capital Sees 42% Upside In Amicus Therapeutics Following Positive Phase 3 Data

Amicus Therapeutics (FOLD) today announced robust 18-month data from the migalastat monotherapy Study 012 in Fabry patients with amenable mutations. Migalastat met the …

Raptor Quarterly Update: Janney Capital Suggests Buying Shares

In a research note released August 8, Janney Capital analyst Kimberly Lee maintained a Buy rating on Raptor Pharmaceuticals Corp. (RPTP) with a …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts